Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

stocks

2 ASX shares that benefit from sticky inflation

Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks

Our view of Dexus / Scentre deal

Dexus acquires stake in Westfiend Chermside.
stocks

Undervalued ASX retailer benefiting from rebound in spending

Uplift in sales momentum continues.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,874.2025.800.29%
CAC 408,091.3014.86-0.18%
DAX 4023,983.8393.04-0.39%
Dow JONES (US)48,061.5852.68-0.11%
FTSE 1009,788.41103.621.07%
HKSE25,468.78233.370.92%
NASDAQ22,902.15209.31-0.91%
Nikkei 22549,512.28128.990.26%
NZX 50 Index13,295.91129.04-0.96%
S&P 5006,761.3538.91-0.57%
S&P/ASX 2008,585.2021.600.25%
SSE Composite Index3,870.2845.471.19%

Market Movers